272 related articles for article (PubMed ID: 17373900)
1. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
Simonds HM; Miles D
Expert Opin Biol Ther; 2007 Apr; 7(4):487-91. PubMed ID: 17373900
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of chemotherapy by anti-HER.
Kataoka A; Ishida M; Murakami S; Ohno S
Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
[TBL] [Abstract][Full Text] [Related]
4. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
Haq B; Geyer CE
Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
6. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
7. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
Kabe KL; Kolesar JM
Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Garnock-Jones KP; Keating GM; Scott LJ
BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
[No Abstract] [Full Text] [Related]
9. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Bernard-Marty C; Lebrun F; Awada A; Piccart MJ
Drugs; 2006; 66(12):1577-91. PubMed ID: 16956305
[TBL] [Abstract][Full Text] [Related]
11. Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR; Swain SM
Semin Oncol; 2003 Oct; 30(5 Suppl 16):54-64. PubMed ID: 14613027
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
13. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
14. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
15. Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA
N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
[No Abstract] [Full Text] [Related]
16. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
[TBL] [Abstract][Full Text] [Related]
18. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
